Albumin use and mortality among intensive care patients with acute heart failure: a retrospective study

J Cardiovasc Med (Hagerstown). 2023 Aug 1;24(8):578-584. doi: 10.2459/JCM.0000000000001518. Epub 2023 Jun 26.

Abstract

Objective: Hypoproteinemia is common in patients with acute heart failure, especially in the intensive care unit (ICU). We assessed short-term mortality in patients with acute heart failure for albumin and nonalbumin users.

Methods: Our study was a retrospective, observational and single-center study. We included patients with acute heart failure from the Medical Information Mart for Intensive Care-IV and compared short-term mortality and length of hospital stay in patients with and without albumin use. We used propensity score matching (PSM) to adjust for confounders, a multivariate Cox proportional hazard regression model, and performed subgroup analysis.

Results: We enrolled 1706 patients with acute heart failure (318 albumin users and 1388 nonalbumin users). The 30-day overall mortality rate was 15.1% (258/1706). After PSM, the 30-day overall mortality was 22.9% (67/292) in the nonalbumin group and 13.7% (40/292) in the albumin group. In the Cox regression model, after propensity matching, the albumin use group was associated with a 47% reduction in 30-day overall mortality [hazard ratio (HR) = 0.53, 95% confidence interval (CI): 0.36-0.78, P = 0.001]. In subgroup analysis, the association was more significant in males, patients with heart failure with reduced ejection fraction (HFrEF), and nonsepsis patients.

Conclusion: In conclusion, our investigation suggests that the use of albumin was associated with lower 30-day mortality in patients with acute heart failure, especially in males, those aged >75 years, those with HFrEF, those with higher N-terminal pro-brain natriuretic peptide levels, and those without sepsis.

Publication types

  • Observational Study

MeSH terms

  • Albumins* / therapeutic use
  • Critical Care
  • Heart Failure* / diagnosis
  • Heart Failure* / drug therapy
  • Heart Failure* / mortality
  • Humans
  • Intensive Care Units
  • Male
  • Retrospective Studies
  • Stroke Volume
  • Ventricular Dysfunction, Left*

Substances

  • Albumins